Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639155 · ClinicalTrials.gov registry record · Phase 1
A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults
A Phase 1 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT03639155 is a Phase 1 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 50 participants.
The verdict
NCT03639155, a Phase 1 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study is to assess the bioequivalence of a test formulation of vadadustat (A) compared to a reference formulation of vadadustat (B)
Interventions
- DRUG vadadustat reference tablets
- DRUG vadadustat test tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03639155
The ClinicalTrials.gov registry entry for NCT03639155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vadadustat reference tablets is the first listed.
NCT03639155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03639155 about?
NCT03639155 is a clinical study titled "A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults". This study is to assess the bioequivalence of a test formulation of vadadustat (A) compared to a reference formulation of vadadustat (B)
What is the current status of trial NCT03639155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2018-04-12. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT03639155?
The interventions under investigation include: vadadustat reference tablets (DRUG), vadadustat test tablets (DRUG).
Who is sponsoring clinical trial NCT03639155?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.